Thalidomide Capsules USP

Thalidomide Capsules USP are a prescription immunomodulatory and anticancer medication primarily indicated for the treatment of multiple myeloma and selected immune-mediated disorders. This oral capsule formulation offers reliable systemic absorption and is widely used in oncology treatment protocols under specialist supervision. Thalidomide is recognized for its role in combination cancer therapies, helping improve clinical outcomes in eligible patients.

Thalidomide works through a dual mechanism of action, including modulation of immune system responses and inhibition of angiogenesis—the formation of abnormal blood vessels that support tumor growth. By suppressing inflammatory cytokines and restricting cancer cell nourishment, thalidomide helps slow disease progression in hematological malignancies. These therapeutic properties make it a valuable option in long-term cancer management strategies.

Due to its strict safety and risk management requirements, Thalidomide Capsules USP must be used only under qualified medical supervision. Patients are carefully monitored throughout treatment to ensure safe and effective therapy. Manufactured in compliance with USP and pharmaceutical quality standards, Thalidomide Capsules deliver consistent potency and are supplied exclusively as a prescription-only oncology medicine for controlled clinical use.

Product Features

• Immunomodulatory anticancer capsule
• USP-grade Thalidomide formulation
• Commonly used in multiple myeloma treatment
• Oral capsule dosage form
• Helps regulate immune response and angiogenesis
• Manufactured under strict pharmaceutical quality standards
• Ensures consistent potency and purity
• Prescription-required medication

How It Helps

• Helps slow cancer cell growth by inhibiting abnormal blood vessel formation
• Modulates immune system activity to support anticancer response
• Reduces inflammatory cytokines involved in disease progression
• Supports effective management of multiple myeloma in combination therapy